Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.45 |
| ▸ | CPS1 | P31327 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924842 | 1.00 | MEN1 (0.55) | MEN1KMT2APOLBMAPTNPC1 | |
| SCHEMBL3915914 | 0.97 | POLB (0.49) | MEN1KMT2APOLBMAPTNPC1 | |
| SCHEMBL13633373 | 0.97 | POLB (0.49) | MEN1KMT2APOLBMAPTNPC1 | |
| SCHEMBL3916319 | 0.90 | MEN1 (0.53) | MEN1KMT2APOLBMAPTNPC1 | |
| SCHEMBL13633366 | 0.90 | MEN1 (0.53) | MEN1KMT2APOLBMAPTNPC1 | |
| SCHEMBL13777027 | 0.88 | MEN1 (0.51) | MEN1KMT2APOLBMAPTNPC1 | |
| SCHEMBL3934287 | 0.86 | POLB (0.47) | MEN1KMT2APOLBMAPTNPC1 | |
| SCHEMBL13633365 | 0.86 | POLB (0.47) | MEN1KMT2APOLBMAPTNPC1 | |
| SCHEMBL13777022 | 0.84 | SLC6A9 (0.46) | MEN1KMT2APOLBMAPTNPC1 | |
| SCHEMBL14346812 | 0.84 | POLB (0.46) | MEN1KMT2APOLBMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281086-A1 | 2 -OXYHETEROARYLAMIDE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281086-A1 | 2 -OXYHETEROARYLAMIDE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090181951-A1 | PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20090181951-A1 | PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-16 | — | — | US | disclosed |
| WO-2007144637-A1 | 2 -OXYHETEROARYLAMIDE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144652-A2 | PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281086-A1 | 2 -OXYHETEROARYLAMIDE DERIVATIVES AS PARP INHIBITORS | PARP2, PARP3, PARP11 | MEN1 1711/4885KMT2A 973/4885POLB 66/4885 |
| US-20090181951-A1 | PARP INHIBITORS | PARP2, PARP3, PARP1 | MEN1 808/4885KMT2A 2114/4885POLB 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.